Observational studyFrontiers in immunology2023

Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study.

Pilar Santiago-Setien et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.